Next Phase Newsletter

A strategic investment fund formed by a South America-based pharma company is seeking to invest in biotech companies.  For early-stage opportunities the fund typically makes equity investments and may syndicate with other investors, whereas for clinical-stage opportunities the fund is more likely to form strategic partnerships that involve rights to an asset.  The fund is open to considering therapeutic opportunities globally, but only if the company is pursuing the US market.

The fund invests in therapeutics; about 80% of the firm’s investments are in clinical-stage assets, with a preference for companies with some human proof-of-concept data; the remaining 20% of investments are made in preclinical opportunities.  Drug-device combinations will also be considered, but not diagnostics.  The firm will invest in both small and large molecules, and has a strong preference for investing in orphan drugs and other niche disease areas.  It is preferred that indications have validated clinical endpoints and can be studied using small trials.  Indications that require large clinical trials, including as cardiovascular diseases and primary care indications (such as influenza) will not be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A UK-based investment group has over £20 million under management. The group currently looks to invest in seed and early clinical stage companies in the life science space. The initial investment ranges from £50,000 to £300,000,but it will reserve capital for follow-on investments, and it can invest up to £1 million over a lifecycle. The group seeks to make 10-20 allocations over the next year. The group focuses on companies based in UK.

The group is currently looking for new opportunities in the Medical Devices, Diagnostics, Lab equipment and Healthcare IT sectors. The group will not invest in drug development companies. For medical devices, the group will consider all classes of devices but prefers devices with short regulatory pathways. The group is also interested companies that don’t require clinical trials. The group is generally opportunistic in terms of indication.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices in California and Hong Kong invests across a variety of sectors, including biotech and medical technology, and will be raising a second fund in 2015.  The firm typically invests $500,000-$1 million, and prefers to invest in seed or Series A rounds. The firm makes up to 12 allocations per year, and is interested in opportunities globally; companies developing products that can impact healthcare delivery in emerging markets such as China or India are of particular interest.

Within the life science field, the firm has a wide range of interests that include immuno-oncology, medical devices (particularly those involving sensors or remote technologies), software, wearables and consumer healthcare devices, and instrumentation/equipment for the healthcare or biotech sectors.  For therapeutic companies, Phase II opportunities are preferred but earlier opportunities may be considered; for medical devices, opportunities may be considered from development-stage through commercialization.  The firm does not invest in diagnostics.  The firm’s previous experience in the life science sector includes immuno-oncology drugs and 3D microscope technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An international, nonprofit global health organization with more than 30 offices around the world acts as a bridging agent between the public and commercial sectors for the development of health technologies for use in low-resource settings.

The organization provides funding to selected technology development projects in the form of non-dilutive research grants to help reduce business risks and encourage critical private-sector investment. Size of funding is variable according to individual project’s needs and funding agency’s specifications. Proposals are generally solicited through request for proposal (RFP) sessions that are open to public and private entities.

The organization managed a portfolio of projects focused on appropriate technology solutions for the health needs of people living in low-resource settings. Areas of expertise include diagnostic technologies (with a special focus on point-of-care diagnostics), digital health solutions, health technologies for women and children, reproductive health technologies, new solutions for contraception and STI/HIV prevention, vaccine and pharmaceutical technologies, and water and sanitation technologies. The organization is working on a wide arrange of communicable disease areas including HIV, neglected tropical diseases, malaria, and tuberculosis, as well as non-communicable diseases including cervical cancer, breast cancer, diabetes, and hypertension. The fund generally avoids funding basic research and large clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm based in Paris, France has €400M AUM and looks to invest in venture stages in the life sciences – seed to later phases. The firm mainly provides equity financing and may provide convertible loans as follow-on investments. The firm typically makes an initial investment of €2-3M and €5-8M over the life of the investment. The firm only invests in European-based companies. The firm is actively seeking new investment opportunities.

The firm is opportunistic in the life sciences. The firm focuses on drug development, diagnostics, and medical devices.  The firm is agnostic in terms of subsectors and indications. The firm prefers companies with a portfolio of 2-3 products. The firm generally looks for therapeutic companies with products that are in the pre to late clinical phases. Currently, the firm is active in many subsectors including therapeutics that addresses autoimmune, inflammatory diseases, cancer, diabetes, Alzheimer’s disease, pulmonary devices and cardiac devices.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare investment firm that was founded in 2007 and based in The Netherlands has raised two funds, with the most recent fund closing in 2012. The firm seeks to make equity investments into Dutch technology-driven healthcare companies. The investment size typically ranges from € 0.1 million to € 0.4 million, and it can go up to € 2 million with consortium over the life of an investment. The firm is looking to make at least 7 investments in the next 2-3 years. The firm focuses on companies that are based in The Netherlands.

In the Life Sciences space, the firm is currently seeking new investments in the Medical Technology, R&D Services and Healthcare IT sectors. The firm looks for all classes of medical devices and is opportunistic in terms of indications; however, the firm is most interested in companies developing innovative technologies that have impacts on healthcare processes and/or have impacts on the patients. The firm has a market focus instead of a technology focus. The firm generally invests in companies in the market introduction Phase, but it can also invest earlier-stage companies that have great impacts on healthcare.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Canadian VC firm is currently investing from a second fund raised in 2014, with a closing target of $150 million.  The fund will make equity investments in early-stage life science companies based in Canada and the USA.  The firm prefers to lead or co-lead investments.  Initial investments will typically be of about $5 million, with capital reserved for potential follow-on investments of up to $15 million total per opportunity.  The firm is likely to make 10-12 investments over the fund’s lifetime.

The firm will make about 75% of its allocations in the therapeutics sector, with the remainder invested in diagnostics, medical devices, and/or tools or healthcare IT.  The firm prefers to invest in early-stage opportunities; in the therapeutics sector, investments may be made in companies with a lead product 12-18 months prior to IND.  The fund is generally agnostic in terms of technological field and indication area, but is less likely to invest in products targeting CNS disorders and pain.

The firm only invests in those therapeutic companies that have identified a lead product candidate.  About two-thirds of investments will be made in Canada-based life science companies, with half of the Canadian portfolio consisting of Quebec-based companies; the remaining one-third of the fund will be invested in USA-based companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com